FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2014780970> ?p ?o ?g. }

• W2014780970 endingPage "1027" @default.
• W2014780970 startingPage "1016" @default.
• W2014780970 abstract "OVER THE PAST DECADE, gene therapy has been increasingly applied in clinical trials. According to data published by the Journal of Gene Medicine (http://www.wiley.co.uk/genetherapy/ clinical/), there were a total of 1020 approved gene therapy clinical trials in the world at the end of January 2005. Among these clinical trials, 66% were for the treatment of cancer. Of these cancer gene therapy trials, 58 used recombinant adenovirus encoding human p53 tumor suppressor gene (rAd-p53). More than 20 kinds of cancer indications have been treated with rAd-p53 agent, such as head and neck squamous cell carcinoma (HNSCC), lung cancer, breast cancer, liver cancers. Various clinical treatment regimens have been evaluated, including administration of rAd-p53 agent alone or in combination with conventional therapies such as radiotherapy, chemotherapy, and surgery. Encouraging clinical responses have been reported by a number of study groups. Lang et al. (2003) reported the results of a phase I clinical trial study in which rAd-p53 was administered to 15 patients with recurrent glioma. rAd-p53 was injected intratumorally at doses between 3 1010 and 3 1012 viral particles (VP). Three days after rAd-p53 injection the tumor was resected and more rAd-p53 was injected into the tumor bed. Of the 15 patients treated, 1 survived more than 3 years without evidence of recurrence, 4 patients experienced no recurrence for more than 6 months after treatment, and 2 of these 4 patients survived for more than 1 year. In a multicenter phase II trial study involving 25 patients with non-small cell lung cancer, 7.5 1012 VP of rAd-p53 was injected intratumorally in combination with cisplatin and vinorelbine. No significant difference in tumor response was observed from rAd-p53-injected lesions and noninjected lesions (52 versus 48%, respectively); however, the rAd-p53-treated lesions appeared to be smaller than the nontreated controls (Schuler et al., 2001). In a separate clinical study of 24 patients with non-small cell lung cancer (Nemunaitis et al., 2000), rAd-p53 was injected intratumorally at doses between 1 106 and 1 1011 plaque-forming units (PFU)/injection in combination with cisplatin. Seventeen patients achieved stable disease, 2 patients achieved partial response, and 4 patients had progressive disease. Intratumoral injection of rAd-p53 in combination with cisplatin was well tolerated and there was evidence of clinical efficacy. rAd-p53 was also used for non-small cell lung cancer treatment in combination with radiation therapy (Swisher et al., 2003). The rAd-p53 dose ranged from 3 1011 to 3 1012 VP/injection. Radiation was given concurrently over 6 weeks to a total of 60 Gy. Of the 19 patients treated, 1 showed complete regression (5%), 11 demonstrated partial regression (58%), 3 showed stable disease (16%), 2 showed progressive disease (11%), and 2 were unevaluable (11%). In a bladder carcinoma trial, 12 patients received either intratumoral or intravesicular injections of rAdp53 at doses of 7.5 1011 to 7.5 1013 VP (Kuball et al., 2002). Higher transduction efficiency was observed when using the intravesicular delivery method. Seven of the 11 evaluable patients had evidence of p53 expression by reverse transcription-polymerase chain reaction (RT-PCR). Nine of the 12 patients were alive at a median follow-up of 30 months. Pagliaro et al. (2003) reported a similar phase I study in which rAd-p53 was instilled intravesicularly at 1 1012 VP/dose in 13 patients with locally advanced transitional cell carcinoma of the bladder. A preliminary antitumor effect was observed at a treatment dose of 1 1012 VP on days 1 and 4. Clayman et al. (1998) reported the results of a clinical study in which rAd-p53 was applied as a single agent to treat advanced recurrent head and neck squamous cell carcinoma. Thirty-three patients received an intratumoral injection of rAd-p53 at doses up to 1 1011 PFU/injection. Of the 17 evaluable patients, 2 patients showed objective tumor regression of greater than 50%, 6 patients presented stable disease for up to 3.5 months, and 9 patients showed progressive disease. In all the reported clinical studies, the most common side effects were pain at the injection site, fatigue, and development of self-limited fever. Overall, rAd-p53 treatment was well tolerated by patients, without serious side effects. On the basis of" @default.
• W2014780970 created "2016-06-24" @default.
• W2014780970 creator A5050935036 @default.
• W2014780970 date "2005-09-01" @default.
• W2014780970 modified "2023-09-30" @default.
• W2014780970 title "Current Status of Gendicine in China: Recombinant Human Ad-p53 Agent for Treatment of Cancers" @default.
• W2014780970 cites W147439079 @default.
• W2014780970 cites W1565897093 @default.
• W2014780970 cites W1616121322 @default.
• W2014780970 cites W1790220839 @default.
• W2014780970 cites W1950719160 @default.
• W2014780970 cites W1967452958 @default.
• W2014780970 cites W1996440019 @default.
• W2014780970 cites W2026022524 @default.
• W2014780970 cites W2033791403 @default.
• W2014780970 cites W2035608099 @default.
• W2014780970 cites W2047424764 @default.
• W2014780970 cites W2048238858 @default.
• W2014780970 cites W2049819449 @default.
• W2014780970 cites W2062550347 @default.
• W2014780970 cites W2081633731 @default.
• W2014780970 cites W2087792530 @default.
• W2014780970 cites W2090375463 @default.
• W2014780970 cites W2091259207 @default.
• W2014780970 cites W2099113454 @default.
• W2014780970 cites W2119084812 @default.
• W2014780970 cites W2126679630 @default.
• W2014780970 cites W2144932698 @default.
• W2014780970 cites W2148200419 @default.
• W2014780970 cites W2162803403 @default.
• W2014780970 cites W2168084973 @default.
• W2014780970 cites W2244995601 @default.
• W2014780970 cites W2314477394 @default.
• W2014780970 cites W2325667407 @default.
• W2014780970 cites W3022598401 @default.
• W2014780970 cites W375914236 @default.
• W2014780970 cites W4235341549 @default.
• W2014780970 doi "https://doi.org/10.1089/hum.2005.16.1016" @default.
• W2014780970 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16149900" @default.
• W2014780970 hasPublicationYear "2005" @default.
• W2014780970 type Work @default.
• W2014780970 sameAs 2014780970 @default.
• W2014780970 citedByCount "383" @default.
• W2014780970 countsByYear W20147809702012 @default.
• W2014780970 countsByYear W20147809702013 @default.
• W2014780970 countsByYear W20147809702014 @default.
• W2014780970 countsByYear W20147809702015 @default.
• W2014780970 countsByYear W20147809702016 @default.
• W2014780970 countsByYear W20147809702017 @default.
• W2014780970 countsByYear W20147809702018 @default.
• W2014780970 countsByYear W20147809702019 @default.
• W2014780970 countsByYear W20147809702020 @default.
• W2014780970 countsByYear W20147809702021 @default.
• W2014780970 countsByYear W20147809702022 @default.
• W2014780970 countsByYear W20147809702023 @default.
• W2014780970 crossrefType "journal-article" @default.
• W2014780970 hasAuthorship W2014780970A5050935036 @default.
• W2014780970 hasConcept C104317684 @default.
• W2014780970 hasConcept C126322002 @default.
• W2014780970 hasConcept C143998085 @default.
• W2014780970 hasConcept C17744445 @default.
• W2014780970 hasConcept C191935318 @default.
• W2014780970 hasConcept C199539241 @default.
• W2014780970 hasConcept C40767141 @default.
• W2014780970 hasConcept C502942594 @default.
• W2014780970 hasConcept C54355233 @default.
• W2014780970 hasConcept C71924100 @default.
• W2014780970 hasConcept C86803240 @default.
• W2014780970 hasConceptScore W2014780970C104317684 @default.
• W2014780970 hasConceptScore W2014780970C126322002 @default.
• W2014780970 hasConceptScore W2014780970C143998085 @default.
• W2014780970 hasConceptScore W2014780970C17744445 @default.
• W2014780970 hasConceptScore W2014780970C191935318 @default.
• W2014780970 hasConceptScore W2014780970C199539241 @default.
• W2014780970 hasConceptScore W2014780970C40767141 @default.
• W2014780970 hasConceptScore W2014780970C502942594 @default.
• W2014780970 hasConceptScore W2014780970C54355233 @default.
• W2014780970 hasConceptScore W2014780970C71924100 @default.
• W2014780970 hasConceptScore W2014780970C86803240 @default.
• W2014780970 hasIssue "9" @default.
• W2014780970 hasLocation W20147809701 @default.
• W2014780970 hasLocation W20147809702 @default.
• W2014780970 hasOpenAccess W2014780970 @default.
• W2014780970 hasPrimaryLocation W20147809701 @default.
• W2014780970 hasRelatedWork W1506200166 @default.
• W2014780970 hasRelatedWork W2039318446 @default.
• W2014780970 hasRelatedWork W2048182022 @default.
• W2014780970 hasRelatedWork W2080531066 @default.
• W2014780970 hasRelatedWork W2748952813 @default.
• W2014780970 hasRelatedWork W2897496508 @default.
• W2014780970 hasRelatedWork W2899084033 @default.
• W2014780970 hasRelatedWork W2998699411 @default.
• W2014780970 hasRelatedWork W3032375762 @default.
• W2014780970 hasRelatedWork W3108674512 @default.
• W2014780970 hasVolume "16" @default.
• W2014780970 isParatext "false" @default.
• W2014780970 isRetracted "false" @default.
• W2014780970 magId "2014780970" @default.

• next